InvestorsHub Logo
Followers 62
Posts 7549
Boards Moderated 1
Alias Born 01/02/2003

Re: dukesking post# 409418

Tuesday, 05/23/2023 12:14:19 PM

Tuesday, May 23, 2023 12:14:19 PM

Post# of 425923
My guess...I assume that Teva did not buy all that IPE in order to market their own generic to compete on the same basis with the other four already approved gV products...plus with Amarin's branded Vascepa

In order to make use of their inventory, Teva will need a large market...They will acquire Amarin and proceed to sell branded Vascepa at low prices in the U.S., Europe, and ROW....Teva will pay lower prices for their API because of their increased volume of purchases.

Teva will advertise and emphasize the superiority of their product over gV.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News